Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan

The INSIGHT international, multicenter, randomized, placebo-controlled pivotal Phase II/III clinical study will be conducted with a 3.7 g/day dose of TOTUM•854 on 400 volunteers; The INSIGHT

Related Keywords

Mexico ,Germany ,Japan ,United States ,Paris ,France General ,France ,United Kingdom ,China ,Italy ,Quebec ,Canada ,Spain ,Riom ,Auvergne ,French ,Carole Rocher Marc Delaunay ,European Regional Development Fund ,European Society Of Hypertension ,World Health Organization ,International Society Of Hypertension ,University Of Avignon ,Research Development ,Young Innovative Company ,Industrial Affairs At Valbiotis ,European Union ,Ecology Lab La ,Innovative Company ,European Society ,International Society ,Industrial Affairs ,Chief Operating Marketing ,Business Officer ,Cardiovascular Pharm Ecology Lab ,Quebec City ,Valbiotis Universal Registration Document ,French Financial Markets Regulator ,Rocher Marc Delaunay ,Valbiotis ,Nnounces ,Hat ,Ubmitted ,Competent ,Authorities ,Three ,Linical ,Protocols ,Motum ,Syndicated ,Reduction ,Flood ,Pressure ,Presents ,Comprehensive ,Development ,Plan ,